论文部分内容阅读
目的探讨血液透析对老年慢性肾功能衰竭患者炎症标志物的影响。方法方便选取2014年10月—2016年1月于博州人民医院肾内科进行血液透析的老年慢性肾功能衰竭患者82例为观察组,同时选取100名于该院体检的健康老年人为对照组,所选取的两组对象年龄均为60~75岁。分别于入院时、14 d、30 d、60 d后检测透析前后血清脂联素、CRP、IL-6等炎症标志物的水平,将两组炎症标志物水平进行对比。结果观察组患者血清脂联素、CRP、IL-6分别为(14.88±2.56)mg/L、(7.35±1.88)mg/L、(60.33±6.77)pg/L,对照组患者血清脂联素、CRP、IL-6分别为(7.10±0.89)mg/L、(2.11±0.25)mg/L、(43.25±5.20)pg/L,观察组患者血清脂联素、CRP、IL-6显著高于对照组,差异有统计学意义(P<0.05);观察组患者炎症标志物血清脂联素、CRP、IL-6的水平随着时间的延长不断升高,但各时间点透析前后水平差异无统计学意义(P>0.05);4个时刻点血液透析前炎症标志物水平相比,2个月后比其他3个时刻点显著升高,差异有统计学意义(P<0.05)。结论血液透析不能降低老年慢性肾功能衰竭患者炎症标志物血清脂联素、CRP、IL-6的水平,因此有必要在临床治疗中进行抗炎治疗。
Objective To investigate the effect of hemodialysis on inflammatory markers in elderly patients with chronic renal failure. Methods Convenient 82 elderly patients with chronic renal failure who underwent hemodialysis in Department of Nephrology of Bazhou People’s Hospital from October 2014 to January 2016 were selected as the observation group and 100 healthy elderly persons undergoing physical examination in the hospital were selected as the control group, The selected two groups of subjects are 60 to 75 years of age. The levels of serum adiponectin, CRP, IL-6 and other inflammatory markers before and after dialysis were measured at 14 d, 30 d and 60 d after admission. The levels of inflammatory markers in both groups were compared. Results The levels of serum adiponectin, CRP and IL-6 in the observation group were (14.88 ± 2.56) mg / L and (7.35 ± 1.88) mg / L and (60.33 ± 6.77) pg / , CRP and IL-6 were (7.10 ± 0.89) mg / L, (2.11 ± 0.25) mg / L and (43.25 ± 5.20) pg / L, respectively. The levels of serum adiponectin, CRP and IL- (P <0.05). The levels of serum adiponectin, CRP and IL-6 in the observation group increased with time, but the difference in levels before and after dialysis at each time point (P> 0.05). The levels of inflammatory markers before hemodialysis at 4 time points were significantly higher than those at other 3 time points after 2 months (P <0.05). Conclusion Hemodialysis can not reduce the levels of serum adiponectin, CRP and IL-6 in elderly patients with chronic renal failure. Therefore, it is necessary to carry out anti-inflammatory treatment in clinical treatment.